SI1237878T1 - 4-pirimidinil-n-acil-l-fenilanin - Google Patents

4-pirimidinil-n-acil-l-fenilanin

Info

Publication number
SI1237878T1
SI1237878T1 SI200030948T SI200030948T SI1237878T1 SI 1237878 T1 SI1237878 T1 SI 1237878T1 SI 200030948 T SI200030948 T SI 200030948T SI 200030948 T SI200030948 T SI 200030948T SI 1237878 T1 SI1237878 T1 SI 1237878T1
Authority
SI
Slovenia
Prior art keywords
phenylalanines
pyrimidinyl
acyl
Prior art date
Application number
SI200030948T
Other languages
English (en)
Inventor
Achyutharao Sidduri
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SI1237878T1 publication Critical patent/SI1237878T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
SI200030948T 1999-12-06 2000-11-28 4-pirimidinil-n-acil-l-fenilanin SI1237878T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16908999P 1999-12-06 1999-12-06
PCT/EP2000/011884 WO2001042225A2 (en) 1999-12-06 2000-11-28 4-pyrimidinyl-n-acyl-l-phenylalanines
EP00989906A EP1237878B1 (en) 1999-12-06 2000-11-28 4-pyrimidinyl-n-acyl-l-phenylalanines

Publications (1)

Publication Number Publication Date
SI1237878T1 true SI1237878T1 (sl) 2007-08-31

Family

ID=22614222

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030948T SI1237878T1 (sl) 1999-12-06 2000-11-28 4-pirimidinil-n-acil-l-fenilanin

Country Status (35)

Country Link
EP (1) EP1237878B1 (sl)
JP (1) JP3824935B2 (sl)
KR (1) KR100522344B1 (sl)
CN (1) CN1218943C (sl)
AR (1) AR034401A1 (sl)
AT (1) ATE357433T1 (sl)
AU (1) AU783348B2 (sl)
BR (1) BR0016195A (sl)
CA (1) CA2392570C (sl)
CO (1) CO5080772A1 (sl)
CY (1) CY1106626T1 (sl)
CZ (1) CZ303435B6 (sl)
DE (1) DE60034061T2 (sl)
DK (1) DK1237878T3 (sl)
EG (1) EG24361A (sl)
ES (1) ES2282162T3 (sl)
HK (1) HK1054384B (sl)
HR (1) HRP20020468B1 (sl)
HU (1) HU229105B1 (sl)
IL (2) IL149617A0 (sl)
JO (1) JO2283B1 (sl)
MA (1) MA26850A1 (sl)
MX (1) MXPA02005564A (sl)
MY (1) MY126972A (sl)
NO (1) NO322866B1 (sl)
NZ (1) NZ518828A (sl)
PE (1) PE20010961A1 (sl)
PL (1) PL207160B1 (sl)
PT (1) PT1237878E (sl)
RS (1) RS50371B (sl)
RU (1) RU2266901C2 (sl)
SI (1) SI1237878T1 (sl)
TW (1) TWI256387B (sl)
WO (1) WO2001042225A2 (sl)
ZA (1) ZA200203533B (sl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
EP1288205B1 (en) * 2000-08-18 2011-02-02 Ajinomoto Co., Inc. Novel phenylalanine derivatives
AR033765A1 (es) * 2001-05-22 2004-01-07 Syngenta Participations Ag Procedimiento para la preparacion de derivados 3-alquil-3h-isobenzofuran-1-ona 7-sustituidos.
JP4452899B2 (ja) 2001-12-13 2010-04-21 味の素株式会社 新規フェニルアラニン誘導体
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
EP1781686B1 (en) * 2004-08-16 2009-05-06 Merck & Co., Inc. Vla-4 antagonists
JP4784224B2 (ja) 2004-09-24 2011-10-05 味の素株式会社 糖鎖転移方法および糖鎖転移酵素
JP2009516729A (ja) * 2005-11-23 2009-04-23 アストラゼネカ アクチボラグ Ｌ−フェニルアラニン誘導体
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
WO2007091046A1 (en) * 2006-02-09 2007-08-16 Astrazeneca Ab Chemical compounds
ES2384400T3 (es) * 2006-06-19 2012-07-04 Toray Industries, Inc. Agente terapéutico o profiláctico para la esclerosis múltiple
EP2548873A1 (en) 2007-09-17 2013-01-23 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
WO2009039127A1 (en) 2007-09-17 2009-03-26 Abbott Laboratories Uracil or thymine derivative for treating hepatitis c
PT2639226T (pt) 2007-09-17 2016-12-09 Abbvie Bahamas Ltd Pirimidinas anti-infeciosas e suas utilizações
JP5689813B2 (ja) * 2008-12-22 2015-03-25 アイシーエル−アイピー アメリカ インコーポレイテッド ビスホスフェートを精製するための水混和性溶媒ベースのプロセス
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
MY167881A (en) 2010-07-16 2018-09-26 Abbvie Bahamas Ltd Process for preparing antiviral compounds
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
MX338725B (es) 2010-07-16 2016-04-28 Abbvie Bahamas Ltd Ligando de fosfina para reacciones cataliticas.
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
CA2854254A1 (en) * 2012-01-27 2013-08-01 F. Hoffmann-La Roche Ag Integrin antagonist conjugates for targeted delivery to cells expressing vla-4
US9447035B2 (en) * 2012-01-27 2016-09-20 Hoffmann-La Roche Inc. Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
EP3064491B1 (en) 2013-10-29 2020-01-08 EA Pharma Co., Ltd. Sulfonamide derivative and medicinal use thereof
CA2981371A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
CR20210213A (es) 2018-10-30 2021-06-24 Gilead Sciences Inc Derivados de quinolina como inhibidores de la integrina alfa4beta7
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2291762A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
JP2002512625A (ja) * 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
TR200000481T2 (tr) * 1997-08-22 2000-06-21 F.Hoffmann-La Roche Ag N-Alkonoilfenilalenin türevleri.
JP3555876B2 (ja) * 1997-08-22 2004-08-18 エフ．ホフマン−ラ ロシュ アーゲー Ｎ−アロイルフェニルアラニン誘導体
AR035838A1 (es) * 1999-01-22 2004-07-21 Elan Pharm Inc Compuestos multiciclicos que inhiben la adhesion de leucocitos mediada por vla-4 y el uso de los mismos para la preparacion de un medicamento

Also Published As

Publication number Publication date
DK1237878T3 (da) 2007-07-30
KR100522344B1 (ko) 2005-10-20
NZ518828A (en) 2004-03-26
YU40402A (sh) 2005-03-15
IL149617A0 (en) 2002-11-10
JP2003516396A (ja) 2003-05-13
HU229105B1 (en) 2013-07-29
MXPA02005564A (es) 2002-09-02
CN1407972A (zh) 2003-04-02
CO5080772A1 (es) 2001-09-25
EP1237878A2 (en) 2002-09-11
NO322866B1 (no) 2006-12-18
PT1237878E (pt) 2007-06-18
CY1106626T1 (el) 2012-01-25
EP1237878B1 (en) 2007-03-21
HK1054384B (zh) 2005-12-09
PL357601A1 (en) 2004-07-26
TWI256387B (en) 2006-06-11
MY126972A (en) 2006-11-30
EG24361A (en) 2009-03-04
NO20022633D0 (no) 2002-06-04
ZA200203533B (en) 2003-08-04
JP3824935B2 (ja) 2006-09-20
JO2283B1 (en) 2005-09-12
CN1218943C (zh) 2005-09-14
HRP20020468B1 (en) 2009-02-28
HUP0204081A3 (en) 2003-07-28
IL149617A (en) 2007-10-31
HK1054384A1 (en) 2003-11-28
HUP0204081A2 (en) 2003-05-28
CA2392570C (en) 2010-05-11
DE60034061T2 (de) 2007-12-13
DE60034061D1 (de) 2007-05-03
BR0016195A (pt) 2002-08-13
AU783348B2 (en) 2005-10-20
CZ20022351A3 (cs) 2003-04-16
CA2392570A1 (en) 2001-06-14
CZ303435B6 (cs) 2012-09-12
KR20020063906A (ko) 2002-08-05
AU2669601A (en) 2001-06-18
ES2282162T3 (es) 2007-10-16
RU2266901C2 (ru) 2005-12-27
ATE357433T1 (de) 2007-04-15
PE20010961A1 (es) 2001-09-26
WO2001042225A3 (en) 2002-02-21
RU2002117422A (ru) 2004-03-10
NO20022633L (no) 2002-06-04
AR034401A1 (es) 2004-02-25
RS50371B (sr) 2009-11-10
WO2001042225A2 (en) 2001-06-14
PL207160B1 (pl) 2010-11-30
HRP20020468A2 (en) 2004-04-30
WO2001042225A8 (en) 2002-06-06
MA26850A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
DE60018571D1 (en) Hernienprothese
DE60033307D1 (en) Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen
DE60008112D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE60008382D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE60037335D1 (en) Polymerizationsverfahren
DE50002490D1 (en) Polyester-polyetherblockcopolymere
DE50008011D1 (en) Thixotropierungsmittel
IL149617A0 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines
DE60018288D1 (en) Polyphenylensulfidlegierungszusammensetzung
DE60027722D1 (en) Aspartyl-protease inhibitoren
DE60034237D1 (en) Ferrofluidabdichtung
DE60007505D1 (en) Propargyletherderivate
DE60028360D1 (en) Ptk-chipthermistor
DE60036727D1 (en) Differentialverstärker
DE50000137D1 (en) Spirofluorenopyrane
DE60011809D1 (en) Oxcarbazepinsuspension
DE59909975D1 (en) Testleck
DE10081629D2 (en) Seilzugbefestigung
DE50009469D1 (en) Common-rail-injektor
DE60012950D1 (en) Polyacetalharzzusammensetzung
DE60001313D1 (en) Imidazodiazepinderivate
DE50010757D1 (en) Stilbenaufheller
DE60044740D1 (en) Hochtemperatur-differentialrefraktometer
DE50008218D1 (en) Common-rail-injektor
DE50012999D1 (en) Stirnwandisolation